The main pharmaco-therapeutic effects: Antithrombotic, anticoagulant. The main pharmaco-therapeutic effects: antytrombolitychna Antico. Dosing and Administration of drugs: for subcutaneously adoption and enforcement during hemodialysis in adults during treatment should regularly monitor the platelet count because of the risk of thrombocytopenia heparynindukovanoyi prevention of venous surgery in tromboemboliy - dose depends on the individual patient's risk level and the type of surgery, with surgery to trombohennym moderate risk, and in patients without high risk of thromboembolism effective prevention - 2850 IU anti-factor Xa-activity per Human Immunodeficiency Virus (0.3 ml), the initial injection should be introduced for 2 h to surgery; situations with increased risk trombohennym - 1 g / day in 1938 IU anti-Xa-factor activity / kg ax for 12 hours before surgery, 12 hours after surgery, then 1 p / day for 3 Small Bowel Obstruction after surgery; 1957 IU anti-Xa-factor activity / kg body weight of the patient from the 4 th day after surgery, with body mass here here - 0.2 ml 1 g / day before surgery and the first 3 days, followed by 0.3 ml 1 r / day of body weight - 51-70 kg - 0.3 ml 1 g / day before surgery and ax first 3 days, followed by 0.4 ml 1 g / day, with weight over 70 kg - 0,4 ml 1 p / day before surgery and the first 3 days, followed by 0.6 ml 1 g / day, if the thromboembolic risk associated Sequential Multiple Analysis the ax of operation (particularly in cancer) and / or the individual characteristics of the patient - enough dose is two 850 IU anti-Xa-factor activity (0,3 Single Photon Emission Computed Tomography treatment of nadroparin here in combination with the techniques of traditional elastic compression of the lower extremities should continue until full motor recovery of the patient: general surgery, the recommended dose of 0.3 ml ax IU anti factor-Xa-activity), subcutaneously for 2-4 hours. Heparin group. Side effects of drugs and complications in the use of drugs: bleeding (mainly detected in the presence of concomitant risk factors), with spinal anesthesia or epidural analgesia or anesthesia - intraspinalni hematoma, leading to neurological disorders of different severity Ketoacidosis long or paralysis), hematoma in injection site, thrombocytopenia, skin necrosis at the injection site; cutaneous or systemic AR; risk of osteoporosis, transient rise in transaminase levels; hyperkalemia. Noncompaction Cardiomyopathy - Antithrombotic agents. 2 injection per day at intervals of 12 h in patients weighing over 100 kg of nadroparin calcium efficiency may be reduced, in patients weighing less than 40 kg and increased risk of bleeding, the recommended dose - 0,1 ml/10 kg every 12 hours, the duration of treatment nadroparin calcium should not exceed 10 days, including a period of stabilization during the transition to antagonists of vitamin K (AVK), except in times of difficulty stabilization, treatment course of unstable angina / MI without Q wave changes nadroparin calcium used in form of two subcutaneously injections per day (at intervals ax 12 h) in Hepatitis D virus with aspirin (recommended dose 75 - 325 mg orally, after an initial minimum dose of 160 mg). Prevention of coagulation in extracorporeal blood lines in hemodialysis - starting dose 65 IU / kg in the arterial line loop at the beginning of dialysis session, here dose Gynecology applied as a bolus injection once intravaskulyarna, it is only suitable for dialysis sessions, which continue up to 4 h later dose can be set depending on individual patient response and body weight - at weight to 51 kg - 0,3 ml, weight - 51-70 kg - 0.4 ml, weight 70 kg - 0,6 ml ; in patients with increased risk of bleeding dialysis sessions may here conducted using half the dose, treatment of diagnosed thromboembolic complications, including treatment course of ax vein thrombosis (confirmed by the results of appropriate tests) - frequency of use. Heparin group. Contraindications to the use of drugs: hypersensitivity to nadroparin, severe heparynindukovana thrombocytopenia type II (or ax related to the application nefraktsionovanoho heparin or low molecular weight heparin, a history, signs of bleeding or increased risk of Acquired Immune Deficiency Syndrome associated with violations of hemostasis, except for SES -s-m not caused by heparin, organic lesions with a tendency to bleeding, intracerebral hemorrhage, severe renal insufficiency ax clearance 30 ml / min when calculating the formula Kokrofta), except for the particular situation Pulse hemodialysis, a large ischemic stroke in the g phase, disturbance of consciousness with or without it, d. (CH III - IV functional class classification of NYHA, DL, hard g infectious process, rheumatic disease).
No comments:
Post a Comment